HJHerby Jeanty

Herby Jeanty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Herby Jeanty has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The triglyceride-glucose index as a predictor of cardiovascular disease: an umbrella review of meta-analyses

    by Shahriar Ghodous, Herby Jeanty, Saisree Reddy Adla Jala, Kavya Priya Somu, Nikitha Chellapuram, Shika M Jain, Pegah Rashidian, Abinash Mahapatro, Maryam Jafari, Seyedsina Moghimnejadhosseini, et al.

    Background: The triglyceride-glucose (TyG) index has gained recognition as a tool for assessing cardiovascular disease risk. This umbrella review synthesized findings from multiple meta-analyses examining the association between the TyG index and cardiovascular outcomes. Methods: In this umbrella review of meta-analyses, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A higher TyG index was associated with increased odds of arterial stiffness [categorical: odds ratio (OR) = 1.83, 95% confidence interval (CI): 1.55–2.17, P < 0.01; I 2 = 68%; per 1-unit increase: OR = 1.51, 95% CI: 1.35–1.69, P < 0.01; I 2 = 82%]; coronary artery stenosis (OR = 3.49, 95% CI: 1.71–7.12, P < 0.01; I 2 = 0%); coronary artery calcification (CAC) (highest vs. lowest: OR = 1.66, 95% CI: 1.51–1.82, P < 0.01; I 2 = 0%; continuous: OR = 1.73, 95% CI: 1.36–2.20, P < 0.01; I 2 = 51%); CAC progression (categorical: OR = 1.66, 95% CI: 1.21–2.27, P < 0.01; I 2 = 0%; continuous: OR = 1.47, 95% CI: 1.29–1.68, P < 0.01; I 2 = 41%); and atrial fibrillation (AF) (categorical: OR = 1.98, 95% CI: 1.35–2.91, P < 0.01; I 2 = 92%; continuous: OR = 1.80, 95% CI: 1.50–2.17, P < 0.01; I 2 = 88%). Conclusion: Current meta-analytic evidence suggests that higher TyG index values are associated with several adverse cardiovascular outcomes. However, substantial heterogeneity and the generally low methodological quality of the included meta-analyses limit confidence in the magnitude and clinical applicability of these associations. The TyG index may serve as an adjunctive cardiovascular risk marker, but further high-quality prospective validation is required before routine clinical implementation.


  • Open Access

    Artificial Intelligence and Healthcare Policy: A Bibliometric Analysis of Global Research Trends

    by Pegah Rashidian, Forough Heidarzad-Pahlaviani, Seyedsina Moghimnejadhosseini, Nikitha Chellapuram, Kavya Priya Somu, Saisree Reddy Adla Jala, Herby Jeanty, Satabdi Sahu, Abinash Mahapatro, Mahsa Talebzadeh, et al.

    Background: Artificial intelligence is increasingly influencing health care and policy, yet the global research landscape linking artificial intelligence and health care policy remains underexplored. This study aimed to map publication trends, major contributors, collaboration networks, citation structures, and emerging themes in this field. Methods: A bibliometric analysis was conducted using the Web of Science Core Collection. The search was performed on 3 May 2026, and covered publications from 2000 to 3 May 2026. The final dataset included 347 peer-reviewed English-language original research and review articles. Biblioshiny, VOSviewer, and CiteSpace were used to analyze publication trends, country and institutional contributions, author and journal productivity, collaboration networks, citation and co-citation structures, keyword patterns, and thematic evolution. Results: Publications increased markedly after 2020 and reached their highest annual output in 2025. The 2026 publication count was lower because data for that year were partial at the time of database retrieval. Researchers from 82 countries and 900 institutions contributed to the field, with the United States leading in output, followed by China, England, Canada, and India. Harvard Medical School was the most productive institution, whereas Harvard University had the highest institutional centrality. Frontiers in Public Health published the most articles, and PLOS ONE was the most frequently co-cited journal. The most cited article was “Artificial intelligence and the future of global health.” Key research themes included machine learning, COVID-19, health policy, risk, large language models, interpretable machine learning, neural network-assisted screening, socioeconomic perspectives, and public health applications. Conclusions: Research on artificial intelligence and health care policy has expanded rapidly, particularly in recent years, and is increasingly centered on predictive modeling, public health decision-making, and emerging artificial intelligence technologies. These findings highlight influential contributors, evolving themes, and future directions for researchers, policymakers, and health care leaders.

  • Open Access

    Effects of curcumin on anthropometric measurements in nonalcoholic fatty liver disease: An umbrella meta-analysis study

    by Abinash Mahapatro, Herby Jeanty, Saisree Reddy Adla Jala, Kavya Priya Somu, Gautam Madineni, Elan Mohanty, Mohammed Dheyaa Marsool, Pourya Shamsi, Maryam Shahriari Namin, Shahin Abbaszadeh, et al.

    Background: Metabolic-associated fatty liver disease (MAFLD) affects approximately 30% of the global population and is associated with obesity and metabolic syndrome. Anthropometric indices such as body mass index (BMI), waist circumference (WC), and weight are crucial markers for evaluating the progression of MAFLD. Curcumin, a bioactive compound with anti-inflammatory and antioxidant properties, has been investigated for its potential to improve metabolic outcomes. This umbrella review aimed to systematically evaluate the effects of curcumin supplementation on anthropometric indices in patients with MAFLD, considering epidemiological strength and power analysis. Methods: An umbrella review of meta-analyses from randomized controlled trials was conducted. PubMed, Scopus, and Web of Science were searched up to September 2024. Meta-analyses assessing curcumin’s effects on BMI, weight, and WC in MAFLD patients were included. Quality was assessed using the A Measurement Tool to Assess Systematic Reviews version (AMSTAR-2) tool, and heterogeneity was evaluated using the I 2 statistic. Statistical analyses were performed using R and Stata 18 software. Results: Curcumin supplementation had no significant effect on BMI (standardized mean difference [SMD]: −0.01; 95% confidence interval [CI]: −0.24 to 0.21, P = .91) with low power (1-β = 0.03) and a low epidemiological grade according to GRADE criteria. Similarly, curcumin showed no significant effect on WC (SMD: −0.27; 95% CI: −0.57 to 0.04, P = .08) with high power (1-β = 0.96) but low epidemiological strength. However, curcumin significantly reduced weight (SMD: −0.12; 95% CI: −0.19 to −0.04, P < .01) with moderate power (1-β = 0.56) and moderate epidemiological strength. No significant effect of dose or effect of supplementation duration was found. Conclusion: Curcumin supplementation may result in a statistically detectable but clinically modest reduction in body weight in patients with MAFLD, while showing limited or no efficacy on BMI and waist circumference. The epidemiological strength of the evidence varies across outcomes and is of low to moderate quality. Further well-designed, high-quality randomized controlled trials are needed to confirm the clinical relevance of curcumin’s effects on anthropometric indices.

  • Open Access

    Exploring the Systemic Immune-Inflammation Index as a novel biomarker for nonalcoholic fatty liver disease: a systematic review and meta-analysis

    by Mohit Mirchandani, Herby Jeanty, Satabdi Sahu, Hessam Nejati, Saisree Reddy Adla Jala, Abinash Mahapatro, Shika M Jain, Amir Nasrollahizadeh, Ghazalgoo Arezoo, Seyyed Mohammad Hashemi, et al.

    Background: Nonalcoholic fatty liver disease (NAFLD) represents one of the most prevalent chronic hepatic disorders globally and is intricately associated with metabolic dysregulation and persistent systemic inflammation. The Systemic Immune-Inflammation Index (SII) has emerged as a promising noninvasive indicator for various inflammation-mediated conditions, including NAFLD. This meta-analysis was undertaken to assess the association between SII and NAFLD. Methods: Observational studies identified through a systematic search of PubMed, Web of Science, Embase, and Scopus up to February 2025 that examined the association between SII and NAFLD were considered eligible for inclusion. Quantitative synthesis of the data was conducted through meta-analytic techniques employing a random-effects model to derive pooled effect estimates, thereby accounting for potential heterogeneity across studies. Results: The meta-analysis demonstrated a statistically significant association between higher SII levels and NAFLD. When SII was analyzed as a continuous variable, the pooled effect size was significant (Hedges’ g = 0.11, 95% CI: 0.04–0.18, P < 0.01), indicating elevated SII levels in individuals with NAFLD compared to controls. When evaluated categorically, individuals with high SII values had increased odds of having NAFLD (OR = 1.45, 95% CI: 1.18–1.78, P < 0.01). Statistical power was sufficient to support the validity of the observed associations. Conclusions: SII shows a significant association with NAFLD and may serve as a valuable, noninvasive biomarker for early detection and risk stratification. Despite promising results, the presence of heterogeneity and possible publication bias highlights the need for more standardized and longitudinal research to validate SII’s clinical utility in NAFLD.


  • Open Access

    Prevalence of nonalcoholic fatty liver disease in rheumatoid arthritis: An updated systematic review and meta-analysis

    by Abinash Mahapatro, Maryam Jafari, Herby Jeanty, Satabdi Sahu, Fatemeh Eslampanah, Mohammad Amouzadeh-Lichahi, Mohit Mirchandani, Nakka Raghuma, Dhruvan Patel, Elan Mohanty, et al.

    Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder associated with various comorbidities, including nonalcoholic fatty liver disease (NAFLD). The prevalence of NAFLD in RA patients remains inconsistently reported, necessitating a comprehensive meta-analysis to estimate its true prevalence. This study aimed to assess the prevalence of NAFLD in patients with RA by synthesizing data from multiple studies. Methods: A systematic search was performed across PubMed, Scopus, and Web of Science for studies published up to January 2025. Eligible studies that reported on the prevalence of NAFLD in RA patients were included. A random-effects model was applied, and sensitivity analyses were conducted to test the robustness of the findings. Statistical analyses were performed using Comprehensive Meta-Analysis Software (CMA) version 4 Results: The pooled prevalence of NAFLD/nonalcoholic steatohepatitis (NASH) in RA patients was found to be 22.8% (95% CI = 7.8%–50.8%) with substantial heterogeneity ( I ² = 99.52%). The prediction interval for the prevalence of NAFLD/NASH ranged from 1% to 99%. Subgroup analysis showed varying prevalence rates based on diagnostic modalities: 33.3% for FibroScan, 43.9% for liver biopsy, and 30.5% for ultrasonography. Conclusion: The prevalence of NAFLD is remarkable in RA patients, with varying rates depending on diagnostic methods. The substantial heterogeneity observed across studies, reflected in the wide range of the prediction interval, underscores the need for further studies to provide a more precise estimate. Given the notable prevalence of NAFLD/NASH in RA patients, clinicians are suggested to consider this issue by implementing regular liver screening as a valuable part of RA patient care. More studies are essential to offer a clearer and more consistent understanding of NAFLD/NASH in this population.


  • Open Access

    The impact of gut microbiome modulation on anthropometric indices in metabolic syndrome: an umbrella review

    by Maryam Sadat Aleali, Abinash Mahapatro, Gautam Maddineni, Ruchir Paladiya, Herby Jeanty, Elan Mohanty, Mohit Mirchandani, Ali Jahanshahi, Pavan Devulapally, Azin Alizadehasl, et al.

    Background: Metabolic syndrome (MetS) is a complex disorder characterized by a cluster of metabolic risk factors. Recent research highlights the gut microbiome’s role in metabolic regulation, suggesting that modulation through probiotics, prebiotics, and synbiotics may provide a novel approach to managing MetS. This umbrella review aims to integrate insights from existing meta-analyses to explore how changes in gut microbiota influence key body measurement indicators in individuals with MetS. Methods: A systematic search of PubMed, Scopus, and Web of Science databases identified meta-analyses that assessed the impact of probiotics, prebiotics, or synbiotics on anthropometric indices in MetS patients. Results: The results indicated that microbial therapy leads to a significant reduction in body mass index (BMI) (SMD: −0.22; 95% CI: −0.35 to −0.09; P < 0.01) and waist circumference (WC) (SMD: −0.47; 95% CI: −0.80 to −0.15; P < 0.01). However, microbial therapy did not significantly affect body fat mass (SMD: −0.30; 95% CI: −0.64 to 0.02; P = 0.06), body fat percentage (SMD: −0.29; 95% CI: −0.62 to 0.03; P = 0.07), waist-to-hip ratio (SMD: −0.09; 95% CI: −0.46 to 0.28; P = 0.63), and weight (SMD: −0.06; 95% CI: −0.21 to 0.08; P = 0.37). Conclusions: Gut microbial modulation, mainly through probiotics and synbiotics, shows promise in reducing BMI and WC in MetS patients. However, its effects on other anthropometric indices remain uncertain, warranting further high-quality research to fully understand microbial interventions’ therapeutic potential.


  • Open Access

    Triglyceride-glucose index as a marker in cardiovascular diseases; a bibliometric study and visual analysis

    by Abdulhadi Alotaibi, Abinash Mahapatro, Mohit Mirchandani, Saisree Reddy Adla Jala, Elan Mohanty, Mohammed Dheyaa Marsool Marsool, Herby Jeanty, Pavan Devulapally, Shika M. Jain, Mohammad-Hossein Keivanlou, et al.

    Objective: This study aims to conduct a bibliometric analysis of the triglyceride-glucose (TyG) index in relation to cardiovascular disorders. Methods: Data for the analysis were extracted from the Web of Science Core Collection database on 13 July 2024. We utilized VOSviewer, CiteSpace, and Biblioshiny tools for the analysis. Results: The study revealed a marked increase in research outputs on the TyG index in recent years, peaking with 137 publications in 2023. China emerged as the leading contributor, followed by the USA. The Chinese Academy of Medical Sciences and Peking Union Medical College were among the top contributing institutions. Shouling Wu and Shuohua Chen emerged as the leading authors, with the journal Cardiovascular Diabetology publishing the most articles on this topic. Keyword analysis identified “insulin-resistance” as the most frequently occurring term, followed by “risk.” Cluster analysis identified eleven key research areas, including “percutaneous coronary intervention,” “obesity indicators,” “arterial stiffness,” and “heart failure.” Conclusion: This bibliometric analysis highlights the expanding role of the TyG index in metabolic and cardiovascular research. Key clusters such as percutaneous coronary intervention, obesity indicators, arterial stiffness, heart failure, new-onset hypertension, predicting outcomes, and subclinical coronary artery disease emphasize its wide applicability across diverse clinical settings. The keyword “risk” was the most frequently occurring term, underscoring the importance of the TyG index in cardiovascular risk assessment, alongside its growing use in prognostic applications. These findings reflect the increasing recognition of the TyG index as a pivotal biomarker in cardiovascular medicine and encourage further exploration of its clinical integration.


  • Open Access

    The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment

    by Gautam Maddineni, Sri J. Obulareddy, Ruchir Damjibhai Paladiya, Rohan Reddy Korsapati, Shika M. Jain, Herby Jeanty, Fnu Vikash, Nayanika Chowdary Tummala, Samatha P. Shetty, Arezoo Ghazalgoo, et al.

    Background and aim: Currently, there are no authorized medications specifically for non-alcoholic fatty liver disease (NAFLD) treatment. Studies indicate that changes in gut microbiota can disturb intestinal balance and impair the immune system and metabolism, thereby elevating the risk of developing and exacerbating NAFLD. Despite some debate, the potential benefits of microbial therapies in managing NAFLD have been shown. Methods: A systematic search was undertaken to identify meta-analyses of randomized controlled trials that explored the effects of microbial therapy on the NAFLD population. The goal was to synthesize the existing evidence-based knowledge in this field. Results: The results revealed that probiotics played a significant role in various aspects, including a reduction in liver stiffness (MD: −0.38, 95% CI: [−0.49, −0.26]), hepatic steatosis (OR: 4.87, 95% CI: [1.85, 12.79]), decrease in body mass index (MD: −1.46, 95% CI: [−2.43, −0.48]), diminished waist circumference (MD: −1.81, 95% CI: [−3.18, −0.43]), lowered alanine aminotransferase levels (MD: −13.40, 95% CI: [−17.02, −9.77]), decreased aspartate aminotransferase levels (MD: −13.54, 95% CI: [−17.85, −9.22]), lowered total cholesterol levels (MD: −15.38, 95% CI: [−26.49, −4.26]), decreased fasting plasma glucose levels (MD: −4.98, 95% CI: [−9.94, −0.01]), reduced fasting insulin (MD: −1.32, 95% CI: [−2.42, −0.21]), and a decline in homeostatic model assessment of insulin resistance (MD: −0.42, 95% CI: [−0.72, −0.11]) (P<0.05). Conclusion: Overall, the results demonstrated that gut microbiota interventions could ameliorate a wide range of indicators including glycemic profile, dyslipidemia, anthropometric indices, and liver injury, allowing them to be considered a promising treatment strategy.